Assessment of immune-alternations and their correlations with therapeutic outcomes of transplantation of autologous Mesenchymal and Allogenic fetal stem cells in patients with type 1 diabetes: a study protocol

Abstract

Introduction

Stem-cell therapy, which has recently emerged as a potentially therapeutic option for diabetes, is demonstrated to significantly alter both cellular and non-cellular elements of the immune system. In addition, it is demonstrated that allogenic stem-cells, once considered immune-privileged, can be rejected by the host immune system almost similar to any other somatic cell. To date, nonetheless, details of these intricate interactions remain obscure. The current study is designed to illuminate both aforementioned favorable and unfavorable stem cell-mediated immune reactions. Findings of this study may shed some light on how stem cells may exert their therapeutic effect in type 1 diabetes through immune system-mediated mechanisms and illuminate the partially-obscure immune-caused rejection of these cells.

Methods and analysis

For the purpose of this study, frozen whole blood samples obtained from patients with type 1 diabetes who received stem cells at the Endocrinology and Metabolism Research Institute of Tehran University of Medical Sciences in two different clinical trials will be thawed and analyzed. These clinical trials were carried out using two different sources of stem cells, namely allogenic fetal and autologous mesenchymal cells. The samples we aim to analyze were obtained from the patients before the procedure and regularly after it, one, three, six, 12, and 24 months later. For the purpose of this study, the following parameters will be measured: C-peptide levels, IDAA1c (a surrogate marker of beta cell function which is calculated as HbA1c (%) + [4 × insulin dose (units per kilogram per day)]), frequencies of islet-specific autoreactive CD8+ T cells (CTL), different lymphocyte subsets, thymic function indicators, T cell repertoire diversity (including Treg/Tconv ratios), plasma levels of several pro- and anti-inflammatory cytokines, diabetes autoantibodies, and HLA typing.

Ethics and dissemination

The stem cell transplantation clinical trials which provided the primary source of our samples were carried out at the Endocrinology and Metabolism Research Institute of Tehran University of Medical Sciences between 2008 and 2012. These series of clinical trials have secured approval of the ethics committee of Tehran University of Medical Sciences (ethical code number: E-0089) and registered on the national clinical trial registry of Islamic Republic of Iran (IRCT) with the identifier codes: IRCT138810271414N8 (for autologous mesenchymal cells) and IRCT201103171414N23 (for allogenic fetal cells). Our findings are to be presented at international scientific events, published in peer-reviewed journals, and disseminated both electronically and in print. Besides, results of the current study will be used for design and implementation of future laboratory investigations and clinical trials at the Endocrinology and Metabolism Research Institute of Tehran University of Medical Sciences.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med. 2009;360(16):1646–54.

    CAS  Article  Google Scholar 

  2. 2.

    Redondo MJ, Fain PR, Eisenbarth GS. Genetics of type 1A diabetes. Recent Prog Horm Res. 2001;56:69–89.

    CAS  Article  Google Scholar 

  3. 3.

    Sepe V, Loviselli A, Bottazzo GF. Genetics of type 1A diabetes. New England J Med. 2009;361(2):211.

    CAS  Article  Google Scholar 

  4. 4.

    Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007;316(5829):1341–5.

    CAS  Article  Google Scholar 

  5. 5.

    Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358(9277):221–9.

    CAS  Article  Google Scholar 

  6. 6.

    Baschal EE, Eisenbarth GS. Extreme genetic risk for type 1A diabetes in the post-genome era. J Autoimmun. 2008;31(1):1–6.

    CAS  Article  Google Scholar 

  7. 7.

    Kyvik KO, Green A, Beck-Nielsen H. Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. Bmj. 1995;311(7010):913–7.

    CAS  Article  Google Scholar 

  8. 8.

    Redondo MJ, Jeffrey J, Fain PR, Eisenbarth GS, Orban T. Concordance for islet autoimmunity among monozygotic twins. N Engl J Med. 2008;359(26):2849–50.

    CAS  Article  Google Scholar 

  9. 9.

    Knip M, Veijola R, Virtanen SM, Hyöty H, Vaarala O, Åkerblom HK. Environmental triggers and determinants of type 1 diabetes. Diabetes. 2005;54(suppl 2):S125–S36.

    CAS  Article  Google Scholar 

  10. 10.

    Ling C, Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes. 2009;58(12):2718–25.

    CAS  Article  Google Scholar 

  11. 11.

    Bach J-F. The hygiene hypothesis in autoimmunity: the role of pathogens and commensals. Nat Rev Immunol. 2017.

  12. 12.

    Control D, Group CTR. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;1993(329):977–86.

    Google Scholar 

  13. 13.

    Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol. 2010;10(7):501–13.

    CAS  Article  Google Scholar 

  14. 14.

    Matsushima M, LaPorte R, Maruyama M, Shimizu K, Nishimura R, Tajima N, et al. Geographic variation in mortality among individuals with youth-onset diabetes mellitus across the world. Diabetologia. 1997;40(2):212–6.

    CAS  Article  Google Scholar 

  15. 15.

    Podar T, Solntsev A, Reunanen A, Urbonaite B, Zalinkevicius R, Karvonen M, et al. Mortality in patients with childhood-onset type 1 diabetes in Finland, Estonia, and Lithuania: follow-up of nationwide cohorts. Diabetes Care. 2000;23(3):290–4.

    CAS  Article  Google Scholar 

  16. 16.

    Sneddon JB, Tang Q, Stock P, Bluestone JA, Roy S, Desai T, et al. Stem cell therapies for treating diabetes: Progress and remaining challenges. Cell Stem Cell. 2018;22(6):810–23.

    CAS  Article  Google Scholar 

  17. 17.

    Sivanathan KN, Rojas-Canales DM, Hope CM, Krishnan R, Carroll RP, Gronthos S, et al. Interleukin-17A-induced human Mesenchymal stem cells are superior modulators of immunological function. Stem Cells. 2015;33(9):2850–63.

    CAS  Article  Google Scholar 

  18. 18.

    Esfahani EN, Ghavamzadeh A, Larijani B. Therapeutic Uses of Stem Cells in Endocrinology-Review Article. Iranian J Public Health. 2014;43(Supple 1):35–48.

    Google Scholar 

  19. 19.

    Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824–33.

    CAS  Article  Google Scholar 

  20. 20.

    Tootee A, Esfahani EN, Ghodsi M, Farideh R, Amini M, Larijani B, et al. Application of Allotransplantation of fetal liver-derived stem-cells for treatment of type 1 diabetes: a single-arm, phase 3 Clini¬ cal trial. Iran J Public Health. 2015;44(2):36–41.

    Google Scholar 

  21. 21.

    Ghodsi M, Heshmat R, Amoli M, Keshtkar A-A, Arjmand B, Aghayan H, et al. The effect of fetal liver-derived cell suspension allotransplantation on patients with diabetes: first year of follow-up. Acta Medica Iranica. 2012;50(8):541–6.

    PubMed  Google Scholar 

  22. 22.

    Esfahani EN, Ghavamzadeh A, Mojahedyazdi N, Hashemian S, Alimoghadam K, Aghel N, et al. Administration of Autologous Mesenchymal Stem Cell Transplan¬ tation for treatment of type 1 diabetes mellitus. Iran J Public Health. 2015;44(2):55–68.

    Google Scholar 

  23. 23.

    Malmegrim KC, de Azevedo JT, Arruda L, Abreu JR, Couri CE, de Oliveira GL, et al. Immunological balance is associated with clinical outcome after autologous hematopoietic stem cell transplantation in type 1 diabetes. Front Immunol. 2017;8:167.

    Article  Google Scholar 

  24. 24.

    Douek DC, Vescio RA, Betts MR, Brenchley JM, Hill BJ, Zhang L, et al. Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution. Lancet. 2000;355(9218):1875–81.

    CAS  Article  Google Scholar 

  25. 25.

    Pannetier C, Cochet M, Darche S, Casrouge A, Zöller M, Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci. 1993;90(9):4319–23.

    CAS  Article  Google Scholar 

  26. 26.

    Pannetier C, Even J, Kourilsky P. T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today. 1995;16(4):176–81.

    CAS  Article  Google Scholar 

  27. 27.

    Wu CJ, Chillemi A, Alyea EP, Orsini E, Neuberg D, Soiffer RJ, et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000;95(1):352–9.

    CAS  Article  Google Scholar 

  28. 28.

    Velthuis JH, Unger WW, Abreu JR, Duinkerken G, Franken K, Peakman M, et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC-multimers. Diabetes. 2010;59:1721–30.

    CAS  Article  Google Scholar 

  29. 29.

    Eyraud D, Granger B, Zahr N, Charlotte F, Bardier A, Gottrand G. Measurement of Indoleamine 2, 3 Dioxygenase activity in colorectal Cancer: a controlled group study. J Clin Cell Immunol. 2015;6:374.

    Article  Google Scholar 

  30. 30.

    Zhang X, He Y, Ding M. Simultaneous determination of tryptophan and kynurenine in plasma samples of children patients with Kawasaki disease by high-performance liquid chromatography with programmed wavelength ultraviolet detection. J Chromatogr B. 2009;877(16–17):1678–82.

    CAS  Article  Google Scholar 

  31. 31.

    Larijani B, Zahedi F, editors. Islamic perspective on human cloning and stem cell research. Transplantation proceedings; 2004: Elsevier.

  32. 32.

    Tootee A, Esfahani EN, Larijani B. Application of Fetal Stem Cells in Diabetes: Iran’s Experience. Iranian J Public Health. 2015;44(Supple 2):1–5.

    Google Scholar 

  33. 33.

    Larijani B, Aghayan H-R, Goodarzi P, Arjmand B. GMP-grade human fetal liver-derived mesenchymal stem cells for clinical transplantation. Stem Cells and Good Manufacturing Practices: Springer; 2014. p. 123–36.

  34. 34.

    Bonab MM, Sahraian MA, Aghsaie A, Karvigh SA, Hosseinian SM, Nikbin B, et al. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study. Current Stem Cell Res therapy. 2012;7(6):407–14.

    CAS  Article  Google Scholar 

  35. 35.

    Tootee A, Esfahani EN, Ghodsi M, Razi F, Adibi H, Heshmat R, et al. Flowcytometric assessment of lymphocyte subsets in Type-1 diabetic patients following Allotransplantation of liver-derived fetal stem-cells. Iran J Public Health. 2015;44(2):48.

    Google Scholar 

  36. 36.

    Alam I, Goldeck D, Larbi A, Pawelec G. Flow cytometric lymphocyte subset analysis using material from frozen whole blood. J Immunoass Immunochem. 2012;33(2):128–39.

    CAS  Article  Google Scholar 

  37. 37.

    Brown LM, Clark J, Neuland C, Mann D, Pankiw-Trost L, Blattner W, et al. Cryopreservation and long-term liquid nitrogen storage of peripheral blood mononuclear cells for flow cytometry analysis effects on cell subset proportions and fluorescence intensity. J Clin Lab Anal. 1991;5(4):255–61.

    Article  Google Scholar 

  38. 38.

    Verschoor CP, Kohli V, Balion C. A comprehensive assessment of immunophenotyping performed in cryopreserved peripheral whole blood. Cytometry Part B: Clinical Cytometry. 2017.

  39. 39.

    Nemes E, Kagina B, Smit E, Africa H, Steyn M, Hanekom WA, et al. Differential leukocyte counting and immunophenotyping in cryopreserved ex vivo whole blood. Cytometry Part A. 2015;87(2):157–65.

    Article  Google Scholar 

  40. 40.

    Kim J-H, Jin H-O, Park J-A, Chang YH, Hong YJ, Lee JK. Comparison of three different kits for extraction of high-quality RNA from frozen blood. SpringerPlus. 2014;3(1):76.

    Article  Google Scholar 

  41. 41.

    Nettenstrom L, Alderson K, Raschke EE, Evans MD, Sondel PM, Olek S, et al. An optimized multi-parameter flow cytometry protocol for human T regulatory cell analysis on fresh and viably frozen cells, correlation with epigenetic analysis, and comparison of cord and adult blood. J Immunol Methods. 2013;387(1):81–8.

    CAS  Article  Google Scholar 

Download references

Funding

This study was funded by the National Instititute for Medical Research Development, NIMAD.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Bagher Larijani.

Ethics declarations

Conflict of interests

The authors declare none.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tootee, A., Nikbin, B., Ghahary, A. et al. Assessment of immune-alternations and their correlations with therapeutic outcomes of transplantation of autologous Mesenchymal and Allogenic fetal stem cells in patients with type 1 diabetes: a study protocol. J Diabetes Metab Disord (2021). https://doi.org/10.1007/s40200-020-00716-9

Download citation

Keywords

  • Stem cells
  • Diabetes
  • Immunomodulation
  • Lymphocytes
  • Cytokines